SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...
Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
Ocugen has announced positive Phase 1 trial results for OCU410, a one-time gene therapy for geographic atrophy secondary to ...
The FDA has accepted the resubmitted new drug application (NDA) from Aldeyra Therapeutics for its first-in-class ...
This retrospective cohort study was designed to provide further information on the association between BP parameters and VF ...
Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...
The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...
HelpMeSee has partnered with new initiatives to address the global cataract blindness crisis, focusing on empowering women in ...
Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.
HelpMeSee’s Mazava Project trains general practitioners in Madagascar to perform cataract surgeries, addressing the country’s ...
Prevent Blindness has designated November 18 to 24, 2024, as the 5th annual Thyroid Eye Disease (TED) Awareness Week. The ...
A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback